Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Aart Jan Van Der Lely; R. Kent Hutson; Peter J. Trainer; G. Michael Besser; Ariel L. Barkan; Laurence Katznelson; Anne Klibanski; Vivien Herman-Bonert; Shlomo Melmed; Mary Lee Vance; Pamela U. Freda; Paul M. Stewart; Keith E. Friend; David R. Clemmons; Gudmundur Johannsson; Stavros Stavrou; David M. Cook; Lawrence S. Phillips; Christian J. Strasburger; Suzanne Hacker; Kenneth A. Zib; Robert J. Davis; John A. Scarlett; Michael O. Thorner

doi:10.1016/S0140-6736(01)06844-1

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Aart Jan Van Der Lely, R. Kent Hutson, Peter J. Trainer, G. Michael Besser, Ariel L. Barkan, Laurence Katznelson, Anne Klibanski, Vivien Herman-Bonert, Shlomo Melmed, Mary Lee Vance, Pamela U. Freda, Paul M. Stewart, Keith E. Friend, David R. Clemmons, Gudmundur Johannsson, Stavros Stavrou, David M. Cook, Lawrence S. Phillips, Christian J. Strasburger, Suzanne HackerKenneth A. Zib, Robert J. Davis, John A. Scarlett, Michael O. Thorner

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods: Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. Findings: Mean serum IGF-1 concentrations fell by at least 50%: 467 μg/L (SE 24), 526 μg/L (29), and 523 μg/L (40) in patients treated for 6, 12 and 18 months, respectively (p

Original language	English
Pages (from-to)	1754-1759
Number of pages	5
Journal	The Lancet
Volume	358
Issue number	9295
DOIs	https://doi.org/10.1016/S0140-6736(01)06844-1
Publication status	Published - 24 Nov 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(01)06844-1

Cite this

Van Der Lely, A. J., Hutson, R. K., Trainer, P. J., Besser, G. M., Barkan, A. L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., Freda, P. U., Stewart, P. M., Friend, K. E., Clemmons, D. R., Johannsson, G., Stavrou, S., Cook, D. M., Phillips, L. S., Strasburger, C. J., ... Thorner, M. O. (2001). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet, 358(9295), 1754-1759. https://doi.org/10.1016/S0140-6736(01)06844-1

@article{47c5d20ceba940ce9a07cefaafe49b2a,

title = "Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist",

abstract = "Background: Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods: Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. Findings: Mean serum IGF-1 concentrations fell by at least 50%: 467 μg/L (SE 24), 526 μg/L (29), and 523 μg/L (40) in patients treated for 6, 12 and 18 months, respectively (p",

author = "{Van Der Lely}, {Aart Jan} and Hutson, {R. Kent} and Trainer, {Peter J.} and Besser, {G. Michael} and Barkan, {Ariel L.} and Laurence Katznelson and Anne Klibanski and Vivien Herman-Bonert and Shlomo Melmed and Vance, {Mary Lee} and Freda, {Pamela U.} and Stewart, {Paul M.} and Friend, {Keith E.} and Clemmons, {David R.} and Gudmundur Johannsson and Stavros Stavrou and Cook, {David M.} and Phillips, {Lawrence S.} and Strasburger, {Christian J.} and Suzanne Hacker and Zib, {Kenneth A.} and Davis, {Robert J.} and Scarlett, {John A.} and Thorner, {Michael O.}",

year = "2001",

month = nov,

day = "24",

doi = "10.1016/S0140-6736(01)06844-1",

language = "English",

volume = "358",

pages = "1754--1759",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9295",

}

Van Der Lely, AJ, Hutson, RK, Trainer, PJ, Besser, GM, Barkan, AL, Katznelson, L, Klibanski, A, Herman-Bonert, V, Melmed, S, Vance, ML, Freda, PU, Stewart, PM, Friend, KE, Clemmons, DR, Johannsson, G, Stavrou, S, Cook, DM, Phillips, LS, Strasburger, CJ, Hacker, S, Zib, KA, Davis, RJ, Scarlett, JA & Thorner, MO 2001, 'Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist', The Lancet, vol. 358, no. 9295, pp. 1754-1759. https://doi.org/10.1016/S0140-6736(01)06844-1

TY - JOUR

T1 - Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

AU - Van Der Lely, Aart Jan

AU - Hutson, R. Kent

AU - Trainer, Peter J.

AU - Besser, G. Michael

AU - Barkan, Ariel L.

AU - Katznelson, Laurence

AU - Klibanski, Anne

AU - Herman-Bonert, Vivien

AU - Melmed, Shlomo

AU - Vance, Mary Lee

AU - Freda, Pamela U.

AU - Stewart, Paul M.

AU - Friend, Keith E.

AU - Clemmons, David R.

AU - Johannsson, Gudmundur

AU - Stavrou, Stavros

AU - Cook, David M.

AU - Phillips, Lawrence S.

AU - Strasburger, Christian J.

AU - Hacker, Suzanne

AU - Zib, Kenneth A.

AU - Davis, Robert J.

AU - Scarlett, John A.

AU - Thorner, Michael O.

PY - 2001/11/24

Y1 - 2001/11/24

N2 - Background: Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods: Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. Findings: Mean serum IGF-1 concentrations fell by at least 50%: 467 μg/L (SE 24), 526 μg/L (29), and 523 μg/L (40) in patients treated for 6, 12 and 18 months, respectively (p

AB - Background: Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. Methods: Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis. Findings: Mean serum IGF-1 concentrations fell by at least 50%: 467 μg/L (SE 24), 526 μg/L (29), and 523 μg/L (40) in patients treated for 6, 12 and 18 months, respectively (p

U2 - 10.1016/S0140-6736(01)06844-1

DO - 10.1016/S0140-6736(01)06844-1

M3 - Article

SN - 0140-6736

VL - 358

SP - 1754

EP - 1759

JO - The Lancet

JF - The Lancet

IS - 9295

ER -

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this